What is Shilpa Medicare Ltd (SHILPAMED) share price return in the past 10 years?

Shilpa Medicare Ltd share price has appreciated 8.9% annually (CAGR) over the past ten years.

What is the share price of Shilpa Medicare Ltd (SHILPAMED)?

Company share prices are keep on changing according to the market conditions. The current trading price of Shilpa Medicare Ltd (SHILPAMED) on 05-Jun-2026 16:59:59 at 16:59 is 536.75.

What is the P/E ratio of Shilpa Medicare?

The latest standalone P/E ratio of Shilpa Medicare as of 05-Jun-2026 is 77.38.

What is the P/B ratio of Shilpa Medicare Ltd (SHILPAMED)?

The latest standalone P/B ratio of Shilpa Medicare Ltd (SHILPAMED) as of 05-Jun-2026 is 3.79.

What is the 52-week high and low of Shilpa Medicare Ltd (SHILPAMED)?

The 52-week high of Shilpa Medicare Ltd (SHILPAMED) is Rs. 536.75 and the 52-week low is Rs. 260.00.

Shilpa Medicare Ltd (SHILPAMED) Share Analysis – Quality, Pipeline & Valuation Zone & DeciZen Rating

Name: Shilpa Medicare Ltd (SHILPAMED)
Brand: Shilpa Medicare

Key Metrics

Valuation Multiples

Market Cap

₹10,290 Cr.

Current Price

₹536.8

52-Week Low / High

₹260 / 537

TTM EPS

₹12.4

TTM Sales

₹1,539 Cr.

Book Value per Share

₹132.5

P/E Ratio

42.29

Lower than its 5-year historical median

Industry PE

46.5

Price to Book (P/B)

3.97

Higher than its 5-year historical median

Price to Sales (P/S)

6.69

Higher than its 5-year historical median

EV/EBITDA

24.52

Higher than its 5-year historical median

Dividend Yield

0.15%

Profitability Efficiency

Return on Equity (ROE)

3.75%

Underperforms industry median

Return on Capital Employed (ROCE)

6.94%

Underperforms industry median

Return on Assets (ROA)

2.45%

Operating Profit Margin

23.6%

Net Profit Margin

6.09%

Gross Profit Margin

20.6%

Growth Momentum
1-yr vs 3-yr growth

Sales Growth (1 Year)

Improving versus 3-year growth rate

11.71%

Operating Profit Growth (1 Year)

Improving versus 3-year growth rate

29.05%

Net Profit Growth (1 Year)

Improving versus 3-year growth rate

144.99%

Asset Quality

Promoter Holding

40.13%

Pledged shares (%) of Promoter's holding (%)

8.73%

Reserves

₹2,572 Cr.

Equity

₹19.6 Cr.

Face Value

₹1

All Time Low / High

₹0.20 / 531.90

Shilpa Medicare stock performance

Key Ratios

Check Before You Invest

Quality

Very Good

Check detailed performance

Valuation

Overvalued

Check Valuation charts

Price Trend

Strong

Check Price chart

Q.1 Is Shilpa Medicare Ltd a good quality company?

Shilpa Medicare Ltd is a good quality company, based on a consistently good multi-year financial track record.

This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.

We have analysed the performance of the company on the following:

How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.

How does Shilpa Medicare Ltd performance compare with that of its Peers?

Q.1 Revenue growth of Shilpa Medicare Ltd vs industry peers?

Shilpa Medicare Ltd revenue CAGR is 7.22%, compared to the industry median CAGR of 5.35%, indicating faster growth and gaining its market share.

Q.1 Promoter shareholding and pledge status of Shilpa Medicare Ltd?

Promoters hold 40.13% of the Shilpa Medicare Ltd, with 8.73% of their stake pledged, indicating low pledge risk.

Q.1 Stock return of Shilpa Medicare Ltd over the last decade?

Over the last 9 year(s), the stock has delivered a CAGR of 7.6% based on the current price.

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
ROCE % ⓘ	19.7%	15.3%	11.1%	10.5%	12.4%	10.7%	5.9%	0.8%	5.5%	6.9%	-
Value Creation Index ⓘ	0.4	0.1	-0.2	-0.3	-0.1	-0.2	-0.6	-0.9	-0.6	-0.5	-
Growth Parameters ⓘ
Sales ⓘ	716	779	789	733	908	901	1,146	1,050	1,152	1,286	1,539
Sales YoY Gr.	-	8.8%	1.2%	-7%	23.8%	-0.8%	27.1%	-8.3%	9.7%	11.7%	-
Adj EPS ⓘ	7.2	6.5	6	5.4	8.9	5.5	2.9	-2.4	1.2	4.5	12.4
YoY Gr.	-	-10%	-7.6%	-10.7%	65.8%	-38.4%	-46.2%	-182.7%	NA	269.1%	-
BVPS (₹) ⓘ	41.5	61.6	66.5	73.5	81.5	90.7	105	102.7	104.2	121.3	132.5
Adj Net Profit ⓘ	111	104	97.7	87.3	145	89	51	-42.1	21.3	88.9	243
Cash Flow from Ops. ⓘ	129	37.5	44.9	147	124	46.9	105	180	137	132	-
Debt/CF from Ops. ⓘ	0.7	6.4	4.3	1.3	3.1	18	6.5	4.4	6.9	4.4	-

CAGR ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	6.7%	7.2%	3.9%	11.7%
Adj EPS ⓘ	-5%	-12.5%	15.6%	269.1%
BVPSⓘ	12.7%	8.3%	4.9%	16.4%
Share Price	8.9%	13.8%	67.2%	17.4%

Key Financial Parameters ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
Return on Equity % ⓘ	18.7	12.8	9.4	7.7	11.4	6.3	3.1	-2.3	1.2	4.3	9.8
Op. Profit Mgn % ⓘ	22.5	20.8	19.2	21.1	23.6	19.1	17.4	8.4	20.5	23.7	28.2
Net Profit Mgn % ⓘ	15	12.9	12.1	11.5	15.8	9.7	4.4	-3.9	1.9	6.9	15.8
Debt to Equity ⓘ	0.1	0.2	0.2	0.2	0.3	0.6	0.4	0.5	0.5	0.3	0.1
Working Cap Days ⓘ	158	193	237	266	230	286	280	309	273	270	120
Cash Conv. Cycle ⓘ	59	84	116	141	126	170	165	186	160	166	29

Profit And Loss

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Sales	716	779	789	733	908	901	1,146	1,050	1,152	1,286
Operating Expenses ⓘ +	556	618	638	579	693	729	948	962	916	982
Manufacturing Costs	67	79	89	95	118	129	172	167	148	176
Material Costs	366	372	356	257	278	271	383	416	394	398
Employee Cost	90	128	149	176	197	235	264	286	281	293
Other Costs ⓘ	33	39	44	51	101	94	128	92	92	116
Operating Profit ⓘ	160	162	151	154	215	172	197	88	236	304
Operating Profit Margin (%)	22.3%	20.7%	19.2%	21.0%	23.6%	19.1%	17.2%	8.4%	20.5%	23.6%
Other Income ⓘ +	11	29	33	16	22	40	21	31	17	36
Exceptional Items ⓘ	-2	-5	0	20	0	61	9	0	6	-28
Interest ⓘ	4	3	3	4	5	22	41	59	92	76
Depreciation ⓘ	23	31	37	42	44	54	80	95	108	113
Profit Before Tax ⓘ	140	146	137	136	188	195	102	-38	54	122
Tax ⓘ	36	42	34	26	33	49	42	-7	22	44
Profit After Tax	105	104	103	110	155	146	61	-31	32	78
PAT Margin (%)	14.6%	13.4%	13.0%	14.9%	17.0%	16.2%	5.3%	-2.9%	2.8%	6.1%
Adjusted EPS (₹)	7.0	6.7	6.5	6.9	9.6	9.1	3.5	-1.9	1.8	4.0
Dividend Payout Ratio (%)	4.30%	4.50%	5.40%	7.30%	5.70%	6.10%	15.70%	0%	0%	12.50%

Valuation of Shilpa Medicare - Consolidated

YTD 1Y 3Y 5Y 10Y Max

Analyst's Notes

No data found!

Balance Sheet

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Equity and Liabilities
Shareholders Fund +	639	987	1,085	1,198	1,329	1,479	1,822	1,783	1,809	2,372
Share Capital ⓘ	8	8	8	8	8	8	9	9	9	10
Reserves ⓘ	632	979	1,077	1,189	1,321	1,471	1,814	1,775	1,800	2,362
Debt +	74	235	166	168	330	718	557	633	921	539
Long Term Debt	0	143	68	81	165	474	354	289	560	232
Short Term Debt	74	92	98	87	165	243	203	344	361	307
Minority Interest	2	-3	-5	-8	-8	-11	-11	-9	-9	-9
Trade Payables	106	112	104	81	93	77	146	143	174	95
Others Liabilities ⓘ	109	141	149	172	245	371	362	354	188	300
Total Liabilities ⓘ	931	1,472	1,499	1,610	1,989	2,632	2,875	2,904	3,083	3,298
Fixed Assets
Net Fixed Assets ⓘ +	393	492	534	558	650	1,111	1,342	1,368	1,385	1,418
Gross Block	582	705	793	853	986	1,421	1,727	1,847	1,947	2,076
Accumulated Depreciation	189	213	259	295	336	311	385	478	562	658
CWIP ⓘ	92	141	210	429	666	541	506	655	719	822
Investments ⓘ	94	253	140	2	10	21	34	43	40	35
Inventories	134	190	189	188	226	333	355	320	345	348
Trade Receivables	125	171	220	204	247	234	386	324	392	441
Cash Equivalents	11	100	74	95	45	124	34	22	32	29
Others Assets ⓘ	81	126	132	135	144	269	218	172	171	206
Total Assets ⓘ	931	1,472	1,499	1,610	1,989	2,632	2,875	2,904	3,083	3,298

Cash Flow

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Cash Flow From Operating Activity ⓘ +	129	37	45	147	124	47	105	180	137	132
PBT ⓘ	140	146	137	136	188	195	102	-38	54	122
Adjustment ⓘ	21	17	19	28	42	6	109	148	221	195
Changes in Working Capital ⓘ	-3	-93	-70	19	-63	-106	-72	103	-98	-138
Tax Paid ⓘ	-30	-34	-41	-36	-42	-48	-34	-32	-41	-47
Cash Flow From Investing Activity ⓘ +	-109	-262	-9	-196	-290	-404	-285	-233	-167	-199
Capex	-114	-116	-137	-78	-345	-349	-331	-225	-172	-216
Net Investments	4	-149	125	98	50	-56	14	-9	4	9
Others ⓘ	1	3	4	-216	5	1	31	2	1	8
Cash Flow From Financing Activity ⓘ +	-20	313	-61	10	176	436	83	46	47	63
Net Proceeds from Shares ⓘ	0	172	0	0	0	0	297	0	0	489
Net Proceeds from Borrowing ⓘ	0	128	-56	-68	82	381	-121	-27	123	-295
Interest Paid ⓘ	-4	-3	-3	-4	-4	-22	-41	-58	-92	-77
Dividend Paid ⓘ	-11	-5	-7	0	-17	0	-9	-10	0	0
Others ⓘ	-5	21	5	82	115	78	-42	141	16	-54
Net Cash Flow ⓘ	-0	88	-25	-39	10	79	-98	-7	17	-4

Financial Ratio

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Ratios
ROE (%)	17.66	12.85	9.93	9.59	12.23	10.41	3.67	-1.71	1.78	3.75
ROCE (%)	19.69	15.28	11.13	10.45	12.38	10.73	5.94	0.8	5.49	6.94
Asset Turnover Ratio	0.79	0.65	0.53	0.47	0.5	0.39	0.42	0.36	0.38	0.4
PAT to CFO Conversion(x)	1.23	0.36	0.44	1.34	0.8	0.32	1.72	N/A	4.28	1.69
Working Capital Days
Receivable Days	52.30	69	90.20	105.50	90.60	97.30	98.80	123.50	113.50	118.20
Inventory Days	67	75.50	87.30	93.70	83.20	113.30	109.70	117.30	105.40	98.30
Payable Days	90.70	107.20	110.60	131	113.90	114	106	126.70	146.70	123.70

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

90.41

7.90

7.92

8.73

* Pledged shares as % of Promoter's holding (%)

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Shilpa Medicare Ltd FAQs

The current trading price of Shilpa Medicare on 05-Jun-2026 16:59 is ₹536.8.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 04-Jun-2026 the market cap of Shilpa Medicare stood at ₹10,289.6 Cr

The latest P/E ratio of Shilpa Medicare as of 04-Jun-2026 is 77.38.

The latest P/B ratio of Shilpa Medicare as of 04-Jun-2026 is 3.79.

The 52-week high of Shilpa Medicare is ₹536.8 and the 52-week low is ₹260.0.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Shilpa Medicare is ₹597 ( Cr.) .

Past 10 year's financial track record analysis by Moneyworks4me indicates that Shilpa Medicare Ltd is a good quality company.

The key valuation ratios of Shilpa Medicare Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.

The Price Trend analysis by MoneyWorks4Me indicates it is Strong which suggest that the price of Shilpa Medicare Ltd is likely to Rise in the short term. However, please check the rating on Quality and Valuation before investing

About Shilpa Medicare Ltd

Shilpa Medicare, established in 1987, has carved a niche for itself in the exceedingly competitive and quality-conscious sphere of pharmaceuticals manufacturing. It produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications.

The company has earned its spurs as a successful and reliable partner within the pharmaceutical industry. Buyers within the country and from across the borders count on its fast track integrated process development and finely honed expertise of its skilled and experienced personnel. The company is already exporting to USA, Canada, Australia, Japan and European countries viz., Germany, Switzerland, Netherlands, Belgium, Spain, Greece, Cyprus, Italy, United Kingdom etc., South American countries like Mexico, Brazil, Columbia etc, African countries like Kenya, Nigeria and West Indies etc, Asian countries like Singapore, Taiwan, China, Malaysia, Thailand and closer to home to Iran, Egypt, Pakistan and Bangladesh. Shilpa Medicare is synergizing strength through tie-ups for manufacturing products and co-marketing rights, for it believes in working together and sharing success.

Being proactive in approach, the company continually seeks out enquiryâ€™s for development of new products drawing from the extensive knowledge-base of its qualified and experienced people as well as sophisticated facilities.

Product range of the company includes:

Oncology AP's

Anastrozole
Bicalutamide
Carboplatin
Gemcitabine HCI
Irinotecan HCl Trihydrate
Oxaliplatin
Temozolomide
Cisplatin
5-Fluoro
Bortezomib
Capecitabine
Decarbazine
Docetaxel
Gefitinib
Hydroxy urea
Imatinib Mesylate
Lenalidomide
Letrozole
Methotrexate
Thalidomide
Topotecan HCl
Zoledronic acid

General APIs

Ambroxol HCl
Ticlopidine HCl
Buflomedil HCl
Nifedipine
Lamivudine
Sildenafil Citrate
Terfenadine
Acebrophylline
Phenylephrine HCl
Ursodeoxycholic acid

PRODUCTS UNDER DEVELOPMENT (Oncology)

Bendamustine Cladribine
Decitabine Disodium Pamidronate
Epirubicin Exemustane
Fludarabine Phosphate Idarubicine
Paclitaxel Pemetrexed
Lomustine Methotrexate
Pamidronic acid Tandutinib

NUTRITIONAL SUPPLEMENTS

Chromium picolinate Chromium polynicotinate

DRUG INTERMEDIATES

Trans-4-amino cyclohexanol
2-Amino-3,5-dibromobenzaldehyde
1,3,5-Trimethoxy Benzene
1,3,5-Tribromo Benzene
7-ethyl camptothecin
7-ethyl-10-hydroxy camptothecin

Awards & Achievements:

Karnataka State Govt. 'Best Enterpreneur Award'.
Govt. of India 'Best Enterpreneur Award'.
â€˜Star Export Houseâ€™ Status from Ministry of Commerce and Industry, Govt. of India
'cGMP' Certificates from W.H.O. for 20 API's
'Best Export Award' from Visvesvaraya Industrial Trade Centre, Bangalore, Govt. of Karnataka, INDIA
'Outstanding Industrial Award' from Indian Junior Chamber.
'Registration with 'Russian Health Authority' for Ambroxol HCl
'Certificate of Suitability' received from EDQM for Ambroxol HCl (R0-CEP 2004-201-Rev 00)
'Certificate of Suitability' received from EDQM for Ticlopidine HCl (R0-CEP 2005-004-Rev 00)
'Certificate of Suitability' received from EDQM for Carboplatin (R0-CEP 2006-212-Rev 00)
Patent application on Irinotecan HCl Trihydrate 'An improved process for the preparation of Irinotecan HCl Trihydrate' published as WO2006016203 on date 2006-02-16
Patent file for Gemcitabine HCl and Anastrozole manufacturing process.
Filed ASMF/EDMF of Gemcitabine HCl over 21 EU countries
Filed ASMF/EDMF of Irinotecan HCl Trihydrate HCl over 27 EU countries
Filed ASMF/EDMF of Oxaliplatin HCl over 11 EU countries
'Best District Export Award' received from FKCCI, Bangalore on 16.06.2007
Korean FDA Approved for Gemcitabine HCl & Ambroxol HCl
COS received from EDQM for Buflomedil HCl (R0-CEP 2006-080-Rev.00)
COS received from EDQM for Oxaliplatin EP (R0-CEP 2006-201-Rev.00)
'Best District Export Award' received from FKCCI, Bangalore on 20.06.2008.
COS received from EDQM for Gemcitabine HCl EP (R0-CEP 2006-222-Rev 00)
2010 - Shilpa Medicare Limited was granted certificate of GMP Compliance of Manufacturer for Gemcitabine Hydrochloride
2012 - Shilpa Medicare Ltd has been conferred First Prize of the National Energy Conservation Award-2012 in the Drugs & Pharmaceuticals Sector from Ministry of Power, New Delhi.

Shilpa Medicare Ltd (SHILPAMED)

Shilpa Medicare Ltd (SHILPAMED)

Shilpa Medicare stock performance

Check Before You Invest

Quality

Valuation

Price Trend

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Value Creation ⓘ

Growth Parameters ⓘ

CAGR ⓘ

Key Financial Parameters ⓘ

Profit And Loss

Valuation of Shilpa Medicare - Consolidated

Price Calculator

Price Chart

Price to Earnings

Price to Sales

Price to Book

EV to EBITDA

Dividend History

Analyst's Notes

Balance Sheet

Equity and Liabilities

Fixed Assets

Cash Flow

Financial Ratio

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Shilpa Medicare Ltd FAQs

About Shilpa Medicare Ltd

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Shilpa Medicare Ltd (SHILPAMED)

Shilpa Medicare Ltd (SHILPAMED)

Shilpa Medicare stock performance

Check Before You Invest

Quality

Valuation

Price Trend

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Value Creation ⓘ

Growth Parameters ⓘ

CAGR ⓘ

Key Financial Parameters ⓘ

Profit And Loss

Valuation of Shilpa Medicare - Consolidated

Price Calculator

Price Chart

Price to Earnings

Price to Sales

Price to Book

EV to EBITDA

Dividend History

Price Calculator

Price Chart

Price to Earnings

Enterprise Value to EBIT

Price to Book-Value

Price to Sales

Dividend History

Analyst's Notes

Balance Sheet

Equity and Liabilities

Fixed Assets

Cash Flow

Financial Ratio

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Shilpa Medicare Ltd FAQs

What is the share price of Shilpa Medicare?

What is the market cap of Shilpa Medicare?

What is the P/E ratio of Shilpa Medicare?

What is the P/B ratio of Shilpa Medicare?

What is the 52-week high and low of Shilpa Medicare?

What is the TTM revenue of Shilpa Medicare?

Is Shilpa Medicare Ltd a good quality company?

Is Shilpa Medicare Ltd undervalued or overvalued?

Is Shilpa Medicare Ltd a good buy now?

About Shilpa Medicare Ltd

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.